Jortan Pharmaceuticals Inc.

Biotech · Defunct

BACE1 inhibitor small molecules to promote pancreatic beta-cell regeneration and proliferation

Grants
$591K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Protection of Pancreatic Beta Cell Mass through Inhibition of BACE-2 for Treatment of Diabetes$295,597
Federal grantDepartment of Health and Human Services · Phase I · Protection of Pancreatic Beta Cell Mass through Inhibition of BACE-2 for Treatment of Diabetes$295,597
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3196BIOTRACKING LLC——
3197Nashville Clinic, LP—$800K
3198Sun Biopharma, Inc.——
3199Jortan Pharmaceuticals Inc.——
3200TheraCea Pharma LC——
3201SAHANE BIOTECH INC——
3202HISTONE THERAPEUTICS——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • BACE-2 Inhibitory Compounds And Related Methods Of Useapplication
  • BACE-2 Inhibitory Compounds And Related Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.